利福昔明在消化道疾病中的应用进展  

The application of Rifaximin in the treatment of digestive tract diseases

作　　者：叶院宁 毛华[1] 汪芳裕[2] YE Yuanning;MAO Hua;WANG Fangyu(Department of Gastroenterology,Zhujiang Hospital of Southern Medical University,Guangzhou 510280;Department of Gastroenterology,Nanjing General Hospital of Nanjing Military Region,China)

机构地区：[1]南方医科大学珠江医院消化内科,广东广州510280 [2]南京军区南京总医院消化内科

出　　处：《胃肠病学和肝病学杂志》2018年第2期212-215,共4页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金(81270453)

摘　　要：利福昔明(Rifaximin)是利福霉素的半合成衍生物,其抗菌谱广,对革兰氏阳性、革兰氏阴性需氧菌和厌氧菌均具有抗菌活性。利福昔明口服不易吸收,局部作用于肠道,因此不良反应轻,安全性好。近年来研究表明,利福昔明可以用于治疗肠易激综合征、旅行者腹泻、小肠细菌过度生长、憩室病、炎症性肠病、肝性脑病等消化道疾病。本文就近年来利福昔明在消化道疾病中的应用进展作一概述。Rifaximin,a derivative of Rifamycin,is a broad spectrum oral antibiotic with antimicrobial activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria.It is poorly absorbed and mainly acted in the gut,thus has a highly favorable safety profile.Recent years,Rifaximin has been shown to be effective in the treatment of digestive tract diseases such as irritable bowel syndrome,traverler’s diarrhea,small intestinal bacterial overgrowth,diverticular disease,inflammatory bowel disease,hepatic encephalopathy.This review addressed the current and emerging role of Rifaximin in the treatment of digestive tract diseases.

关 键 词：利福昔明 肠易激综合征 旅行者腹泻 炎症性肠病 肝性脑病 小肠细菌过度生长 憩室病 

分 类 号：R57[医药卫生—消化系统]